Purpose: To evaluate the antitumor activity in terms of response rate (RR), time to progression (TTP) and survival of paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil (5-FU)/leucovorin in pretreated metastatic breast cancer (MBC).
Background
The incidence of breast cancer has been increasing in Europe and the United states throughout the past decade and, therefore, the incidence of metastatic breast cancer also is expected to be a growing therapeutic problem. While many combination chemotherapy regimens are associated with high response rates in metastatic disease, complete remissions occur in fewer than 20% of patients and median survival is generally in the range of two years [1] . Results of second line chemotherapy are more disappointing. Complete remissions are very rare and overall response rates for most regimens range from 10% to 35% [1] . Given the dearth of active agents capable of inducing durable remissions in metastatic breast cancer, the need for new therapeutic strategies, as well as new drugs which can be incorporated into such strategies, is clear.
Many studies suggested that 5-fluorouracil (5-FU), when administered by continuous infusion, has significant clinical activity in heavily pretreated breast cancer, with reported response rates of 25% to 40% [2] [3] [4] [5] [6] . A substantial body of experimental data indicates that adding pharmacologic concentrations of reduced folates to human tumor cells in vitro enhances both, the duration and the degree of thymidylate synthase inhibition produced by 5-FU [7] [8] [9] . Especially in colorectal carcinoma, leucovorin has been shown to enhance the therapeutic activity of 5-FU [10] [11] [12] . To extend this area of biochemical modulation, and building on results using a monthly schedule of 5-FU/leucovorin for advanced colorectal carcinoma, several groups conducted phase II trials using this combination therapy in pretreated breast cancer patients with metastatic disease [6] . Results of these studies suggest, that this combination has a significant therapeutic effect and an acceptable level of toxicity in this palliative treatment situation. Further, phase II studies with leucovorin and 5-FU in colorectal cancer suggest, that weekly administration of high-dose leucovorin, combined with high-dose 5-FU given as a 24-hour intravenous continuous infusion, might induce higher overall response rates [10] [11] [12] , Thus a phase I/II study was performed with weekly high dose 5-FU/leucovorin in heaviliy pretreated patients with breast cancer [13] . The observed response rate in this phase II trial of 32 patients was 41% (95% CI 24%-58%). These patients had received at least two prior chemotherapy regimens for metastatic breast cancer. Results were the same in the anthracycline resistant subpopulation. Anthracycline resistance was defined as progression while receiving anthracyclines as a prior treatment. These encouraging data using weekly 24-hour infusional 5-FU/leucovorin in the treatment of heavily pretreated breast cancer patients and the promising antineoplastic activity of the tubulin-binding agent paclitaxel as second line single agent chemotherapy in metastatic breast cancer [14] [15] [16] led to the initiation of the phase I-II study using paclitaxel in combination with weekly high-dose 24-hour infusional 5-FU plus leucovorin. In January 1994 we started with a phase I study. Purpose was to show, whether the recommended dosages of either weekly high-dose 24-hour infusional 5-FU/leucovorin (2 g/m 2 /500 mg/m 2 ) [13] and paclitaxel (175 mg/m 2 ) [14] can be used in combination without increasing toxicities to untolerable degrees. All together 16 patients entered phase I and received 52 treatment cycles. No dose limiting toxicities occured at dose levels 1 through 4. Since dose level 4 reached the recommended doses for single agent therapy and because of the activity of the combination and the moderate toxicity, we select dose level 4 for further evaluation during phase II.
Patients and methods
In October 1994, we initiated this phase II study as salvage treatment in patients with metastatic breast cancer and prior exposure to at least one chemotherapy regimen.
Eligibility criteria
All patients had histologically proven breast cancer, had bidimensionally measureable disease and adequate hematological, renal and hepatic functions as well as no severe uncontrolled co-morbidities. Adequate hematological, renal and hepatic functions were defined as absolute neutrophil count >2.0 x 1O 9 /1, platelets count > 100 x 10 9 /l, total bilirubin, AST (SGOT), ALT (SGPT) and serum creatinine ^1.5x upper normal limit. Twenty-nine out of 54 patients have had chemotherapy in the adjuvant setting and all patients have received one chemotherapy regimen for metastatic disease prior to study entry. Additonal eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0,1-2, life expectancy of at least three months and age > 18 years. Prior to study entry pregnancy had to be excluded. All patients gave informed consent before participating in this study, which was approved by the institutional review board.
Study design
Patients were treated with weekly high-dose 5-FU (24-hour infusion)/ leucovorin (two-hour infusion prior to 5-FU) for six weeks and paclitaxel (three-hour infusion) was administered additionally on day 1 and day 22 after standard premedication with corticosteroids, HI-and H2-receptorantagonists. Each cycle comprised of six weeks followed by two weeks rest. All patients were treated under outpatient conditions using i.v. port systems and portable pumps ( Figure 1 
Mode of administration/drug therapy
All patients had intravenous port systems. Leucovorin (500 mg/m 2 ) was dissolved in 500 ml saline 0.9% and was given as two-hour continous infusion prior to infusion of 5-FU (2 g/m 2 ) given over 24 hours by a portable pump system. This application was performed weekly for six weeks. Paclitaxel (175 mg/m 2 ) was given additionally on days 1 and 22. A standard premedication with corticosteroids, HI and H2 receptor antagonists was used and paclitaxel, dissolved in 1000 ml saline solution 0.9%, was given prior to leucovorin/5-FU as a threehour continous infusion, using PVC free infusion material and filter systems ( 5-FU and leucovorin only mild antiemetic therapy was used: alizaprid 3 x 100 mg p.o./day. The number of applied cycles depended on reponse and toxicity. Cytokines were not administered. Dose adjustments consisting of a reduction of the 5-FU dosage by 20% were to be performed in case of mucositis or stomatitis or diarrhea > 2° CTC. If mucositis, stomatitis or diarrhea > 1 ° CTC were present on the day of planned treatment, chemotherapy was delayed until full recovery from side effects and the dose of 5-FU was reduced by 20% for the remaining treatment period. Dose adjustments consisting of a reduction of the paclitaxel dosage to 135 mg/m 2 were to be performed if ANC < 0.5 x 1O 9 /1 for > 7 days, any episode of febrile neutropenia, absence of a recovery of granulocytes (< 1.5 x 10 9 /l) and/or platelets (< 100 x 10 9 /l) by day 50 and in case of nonhematological toxicities > 2° CTC, besides alopecia.
Evaluation at study entry during and after chemotherapy
Prior to treatment, all patients underwent a physical examination, chest X-ray, abdominal ultrasound, thoracic and/or abdominal CT scan if indicated, bone scan, ECG, echocardiogram, blood cell counts, routine biochemical tests and tumor marker screening. Tumor response was evaluated after each treatment cycle using those techniques required to assess tumor locations present at study entry. A full restaging was done after induction of an objective response. In case of no cardiotoxicity a routine check of cardiologic parameters was performed at the end of treatment. Blood cell counts and assessment of toxicities were done weekly during treatment, prior to each and after the last chemotherapy cycle. Biochemical parameters and tumor markers were measured after each treatment cycle. Toxicity was graded according to the NCI CTC-scale.
Response criteria/statistical analysis Responses were assessed according to the standard WHO criteria. All patients had to have a bidimensionally measureable parameter (e.g., liver, lung, lymphnode). Tumor response was documented by two investigations at least six weeks apart and the responses were confirmed by an independend institutional review. The response duration for complete or partial remission was calculated from the date the response was first documented. Survival and time to progression were calculated from the first day of treatment using the method of KaplanMeier [17] .
Results

Patient characteristics
Between October 1994 and January 1996, 54 patients were enrolled into phase II. All patients had previously failed chemotherapy regimens (Table 1 ) and had had progressive disease and tumor-related symptoms prior to study treatment. In all, 59% of patients (32 of 54) had anthracycline resistant disease prior to study entry, defined as disease progression while receiving anthracyclines or within four weeks after the last administration of anthracycline containing chemotherapy (Table 1 ). All patients had at least one bidimensionally measureable tumor site. The characteristics of the patients and pattern of pretreatment are outlined in Table 1 . The median age was 48 years and two thirds of patients were postmenopausal. Patients had a median of two disease sites (range \-4) and 55% (30 of 54) of all patients had liver metastases. 
Treatment and tolerance
All 54 enrolled patients were assessable for response, toxicity and were included in the survival curve. There were no treatment related deaths. The median number of cycles with paclitaxel plus weekly high-dose 5-FU/ leucovorin was 3 (range 1-5) with a total number of 151 treatment cycles applied. Median treatment duration was 6 months. Two patients stopped treatment after the second cycle because of progressive disease and nine additional patients did not continue treatment after the second cycle because of stabilisation of their disease and relief of disease related symptoms in this palliative treatment situation. No dose reductions had to be performed with respect to the paclitaxel dose. The first treatment cycles of 5 patients were accompanied by diarrhea CTC grade 3. According to the guidelines, chemotherapy was delayed until full recovery from side effect and the dose of 5-FU was reduced by 20% for the remaining treatment period. One hundred forty six treatment cycles (97%) were applied without the need for 5-FU dose adjustments or treatment delays.
Toxicity
The major hematologic toxicity was neutropenia, which was mild to moderate in most cycles (73% CTC grade 0-2, 27% grade 3 + 4) ( Table 2 ). No hospitalizations due to febrile neutropenia were necessary. The duration of grade 3 and 4 neutropenia was generally brief with a range of three to five days. No cytokines were used. Neutropenia had no consequences with respect to treatment delay since weekly 24-hour infusional 5-FU/leucovorin has negligible hematotoxicity and could be administered safely despite short neutropenia induced by paclitaxel. Toxicity to platelets and erythrocytes was mild. No patients required platelet transfusions. Three out of 54 patients required a single red blood cell transfusion during the treatment period.
Nonhematologic toxicity ( Table 2 ) mainly consisted of mild to moderate myalgia, mucositis, diarrhea, nausea and vomiting. Peripheral neuropathy (22% of cycles in 28 patients; CTC grade 1 + 2) and hand foot syndrome (56% of cycles in 41 patients; CTC grade 1 + 2) were cumulative and occured mostly during the third treatment cycle. There was a complete relief of cumulative toxicities after termination of the study treatment and no instance of persisting neurotoxicity was documented. No cardiotoxicity was observed. Mild fatigue accompanied the treatment period in most patients (89% of cycles in 48 patients; CTC grade 1 + 2) and tended to be a cumulative side effect that occured after the first treatment cycle.
Response to therapy
Thirty-two out of 54 assessable patients (59%) had an objective response to therapy (partial responses (PR), n -30, 55%; complete responses (CR), n = 2, 4%). Twenty patients (37%) had a stable disease and only two out of 54 patients had disease progression. Overall response rate was 59% with a 95% CI (48%-72%) ( Table 3) . Response in the 32 patients with anthracycline resistant disease included one CR (3%) and 18 PR (56%) in addition to stable disease in 38% and progressive disease in only one patient. (Table 3 ). There were no significant differences in response rates based on number of disease sites and disease category -we observed a response rate of 60% in either lung metastases or hepatic involvement. Only two patients with a single metastatic involvement (one patient with lymphnode metastases and one patient with pulmonary metastases) achieved complete remissions. The median response duration was 12 months with a range of 3 to 22 months. Response duration in patients with anthracycline resistant disease tended to be shorter (10 months) then in patients with anthracycline sensitive disease (16 months). Figure 2 outlines the time to progression, which is eight months (range 2-22 months) at median. Additionally Figure 2 shows the survival curve for the whole study population. Thirty-five out of 54 patients have died all due to tumor progression. The median survival time for the entire group of patients is 15 months (range 2-28 months).
Conclusions
Optimum paclitaxel-containing regimens for the treatment of breast cancer are in the process of being defined. In this phase II study we added paclitaxel to the weekly 24-hour infusional 5-FU plus leucovorin regimen we previously described [13] . By adding an additional active agent with a novel mechanism of action it was expected that the efficacy of the weekly 24-hour infusional 5-FU/ leucovorin regimen, particularly in patients who had previously received anthracyclines could be increased. The moderate toxicity profile, predominantly the lack of myelotoxicity observed with the weekly 24-hour infusional 5-FU/leucovorin regimen allowed the addition of an effective but myelosuppressive agent. We chose to administer paclitaxel as a three-hour infusion based on the previous demonstration of the safety and efficacy of this schedule [14] . During the phase I part of the study, it could be shown, that the recommended single agent dosages of weekly high-dose 24-hour infusional 5-FU/ leucovorin (2 g/m 2 /500 mg/m 2 ) [13] and paclitaxel (175 mg/m 2 ) [14] could be used in combination without compromising dose and dose intensity of either agent and without increasing the toxicity to an intolerable degree. The latter fact is of crucial importance in the light of the palliative treatment intention associated with salvage chemotherapy in patients with advanced breast cancer. Further, the combination of paclitaxel with weekly highdose 5-FU/leucovorin is well tolerated and can be administered safely under outpatient conditions. The patients treated in this study were relatively young (median age 48 years) and many had clinical features typically associated with poor prognosis. Most patients (86%) had visceral metastases in one or more sites and 30 out of 54 patients (55%) had liver metastases. Fiftyfour percent of patients had received previous adjuvant chemotherapy and 68% of patients had received previous anthracyclines as first line treatment for metastatic disease. Thirty-two out of 54 patients fulfilled the criteria of anthracycline resistance with disease progression while receiving anthracyclines as prior treatment or within four weeks after anthracycline containing chemotherapy. The interval from last anthracycline exposure to study entry in those patients was three weeks at median (range 2-4 weeks) ( Table 1 ). In this trial 32 out of 54 enrolled and assessable patients (59%) had an objective response following outpatient treatment with paclitaxel in combination with weekly 24-hour infusional 5-FU plus leucovorin in the second-line treatment of metastatic breast cancer. Thirty of 32 responses were partial, with a median duration of 10 months. Most notably the 59% response rate achieved among patients, who had anthracycline resistant disease. These results are particularly noteworthy when compared with results reported with other combinations in the second-line treatment of advanced breast cancer [1] .
One of the most frequently used cytotoxic drugs, 5-FU, has documented activity in a variety of malignancies, most notably in breast cancer and gastrointestinal tract cancers [6, 12] . However, despite broad clinical experience during past decades, our knowledge about mechanisms of resistance in relation to various 5-FU schedules that are used is limited. In vitro data [18] and clinical experience show, that resistance to one schedule of 5-FU can be overcome by using an alternative schedule, most often a protracted infusion. Our laboratory group established data [19] that underscore the importance of distinguishing the different mechanisms of resistance to 5-FU, taking into account the schedule and mode of drug administration. One notable finding was the fact, that in vitro cellular resistance took longer to develop with protracted application of 5-FU than with bolus application. Furthermore, cells that had developed resistance to short term 5-FU exposure were still sensitive to a 24-hour application [19] .
With regard to clinical studies, results of several phase II trials indicate, that 5-FU/leucovorin is active in breast cancer patients pretreated with anthracycline containing regimens with response rates ranging from 17% up to 44% [2] [3] [4] [5] [6] . In these trials, leucovorin and 5-FU were usually administered by bolus injection. However, our experimental and moreover some clinical phase II data indicate higher activity when 5-FU is given as a protracted infusion [3, 13, [20] [21] [22] . For example Regazzoni et al. [21] reported a 21% objective response rate in the third-line treatment of metastatic breast cancer using a low-dose continuous intravenous infusion of 5-fluorouracil.
The incorporation of paclitaxel into the weekly 24-hour infusional 5-FU/leucovorin regimen resulted in improved response rates, also in the anthracycline resistant subgroup of patients. Usually anthracycline resistance is considered a very poor prognostic factor for response to further chemotherapy. With this study regimen, however, we demonstrated significant activity in metastatic breast cancer patients, whose conventional chemotherapy has failed. Noteworthy the remarkable long median response duration of 12 months and the median survial time of 15 months. Furthermore the study treatment combination is an active outpatient regimen with mild and manageable toxicity in most patients.
With the background of the earlier and more frequent use of anthracyclines in the adjuvant setting as well as the use of high dose chemotherapy with peripheral stem cell support in high-risk patients [23] there is clearly a need to develop active and non cross resistant regimens for salvage chemotherapy. This phase II experience shows that paclitaxel in combination with weekly 24-hour infusional 5-FU plus leucovorin could be a meaningful and active option as second line treatment in advanced breast cancer including those with anthracycline resistance and prospective randomized trials addressing both -the optimal schedule and dose of paclitaxel and 5-FU/ leucovorin -are warranted.
